+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cell Type (B-cell Lymphomas, NK-cell Lymphomas, T-cell Lymphomas), Route of Administration, Patient Age Group, End User - Global Forecast 2025-2030- Product Image
Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cell Type (B-cell Lymphomas, NK-cell Lymphomas, T-cell Lymphomas), Route of Administration, Patient Age Group, End User - Global Forecast 2025-2030- Product Image
Sale

Non-Hodgkin Lymphoma Treatment Market by Treatment Type (Chemotherapy, Immunotherapy, Radiation Therapy), Cell Type (B-cell Lymphomas, NK-cell Lymphomas, T-cell Lymphomas), Route of Administration, Patient Age Group, End User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 191 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 4968597
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Non-Hodgkin Lymphoma Treatment Market is evolving rapidly, underpinned by technological advancements, changing regulatory frameworks, and an increased focus on precision medicine. Senior leaders across pharmaceuticals, biotechnology, and healthcare policy must understand the key forces shaping this competitive landscape to seize new opportunities and manage emerging risks.

Market Snapshot: Non-Hodgkin Lymphoma Treatment Market Size and Growth

The Non-Hodgkin Lymphoma Treatment Market expanded from USD 9.46 billion in 2024 to USD 10.26 billion in 2025. The sector is projected to continue its trajectory at a CAGR of 8.75%, reaching USD 15.66 billion by 2030. This growth is propelled by innovation in therapeutic modalities, a deeper understanding of disease subtypes, and a heightened demand for personalized medicine.

Scope & Segmentation

  • Treatment Types: Chemotherapy, immunotherapy, radiation therapy, stem cell transplant, and targeted therapy are all present in the current therapeutic arsenal.
  • Cell Types: The market includes B-cell lymphomas (such as Burkitt, diffuse large B-cell, follicular, mantle cell, and marginal zone lymphomas), NK-cell lymphomas, and T-cell lymphomas (including anaplastic large cell, cutaneous T-cell, and peripheral T-cell variants).
  • Routes of Administration: Intravenous infusion dominates, with oral and subcutaneous injection formats gaining ground for improved patient experience and adherence.
  • Patient Age Groups: Treatments adapt to adult, geriatric, and pediatric populations, with distinct considerations for efficacy and safety profiles.
  • End Users: The primary care settings include ambulatory surgical centers, cancer treatment centers, and hospitals, each offering unique patient management capabilities.
  • Regional Coverage: In-depth analyses extend across the Americas (including the United States, Canada, Mexico, Brazil, Argentina), EMEA (spanning the United Kingdom, Germany, France, Italy, Spain, Russia, UAE, Saudi Arabia, South Africa, and others), and Asia-Pacific (covering China, India, Japan, Australia, South Korea, and key Southeast Asian markets).
  • Featured Companies: The study tracks developments across AbbVie Inc., AstraZeneca PLC, Bayer AG, BeiGene Ltd., Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Kyowa Kirin Co. Ltd., Lupin Ltd., Merck & Co. Inc., Novartis AG, Salvavidas Pharmaceutical Pvt. Ltd., Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Zydus Pharmaceuticals.

Key Takeaways for Decision-Makers

  • There is a marked shift from conventional cytotoxic therapies toward precision-guided and immunomodulatory treatment pathways, reflecting new scientific insights and patient stratification techniques.
  • Collaboration among pharmaceutical leaders and biotechnology innovators is accelerating the development and commercialization of targeted therapies, including bispecific antibodies and CAR-T cell options.
  • Technological advancements such as digital health platforms and real-world evidence collection are streamlining clinical trial processes and supporting more adaptive, patient-centric research models.
  • Regional market adoption varies widely due to differences in reimbursement systems, regulatory timelines, and health infrastructure. Localized approaches are essential for effective market entry and expansion.
  • Operational best practices and agile manufacturing strategies are vital to manage ongoing cost pressures and ensure consistent patient access across global supply chains.

Tariff Impact on the Non-Hodgkin Lymphoma Treatment Market

Imminent tariff adjustments in the United States are set to influence the sector’s supply chain and cost base. Increased import duties on pharmaceutical ingredients and biologics could raise production costs and contribute to upward price pressure. Manufacturers are expected to increase investment in near-market production and regional contract development partnerships to reinforce supply resilience. These dynamics require active negotiation between industry stakeholders and policymakers to balance innovation with patient affordability, while maintaining operational continuity and timely market access.

Methodology & Data Sources

This report applies a robust, multi-phased research approach. Comprehensive desktop reviews of regulatory filings, scientific literature, and corporate public disclosures form the foundation. Primary insights stem from interviews with clinical leaders, payers, and health economics experts, then validated through real-world data and anonymized claims analysis. Quantitative modeling—including tariff scenario testing—ensures a well-rounded and actionable market assessment.

Why This Report Matters

  • Delivers focused intelligence for senior strategists, supporting informed decision-making on investment priorities, partnership models, and geographic expansion.
  • Identifies operational risks and opportunities related to regulatory trends, reimbursement shifts, and supply chain challenges so leaders can adapt quickly to change.
  • Empowers commercial teams and R&D leaders to align resources toward high-growth segments and engage stakeholders with evidence-based strategies.

Conclusion

With rapid advances in therapy, manufacturing, and regulatory science, the Non-Hodgkin Lymphoma Treatment Market demands a proactive, insight-driven approach. This report equips decision-makers to capitalize on emerging trends, anticipate risks, and drive value across the evolving oncology landscape.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Rapid adoption of CAR T-cell therapies driving treatment paradigm shifts in relapsed and refractory non-Hodgkin lymphoma
5.2. Emergence of bispecific antibody therapies expanding off-the-shelf immunotherapy options for aggressive B-cell lymphomas
5.3. Integration of minimal residual disease monitoring guiding personalized maintenance strategies in follicular lymphoma management
5.4. Expansion of targeted small molecule inhibitors enhancing frontline combination regimens in indolent and aggressive non-Hodgkin lymphoma subtypes
5.5. Growing role of antibody-drug conjugates improving response rates and reducing toxicity in relapsed diffuse large B-cell lymphoma
5.6. Development of novel epigenetic modulators offering new therapeutic pathways for treatment-resistant marginal zone lymphoma cases
5.7. Increased integration of digital diagnostics and AI-driven biomarkers accelerating early detection and therapy customization in non-Hodgkin lymphoma
5.8. Payer and reimbursement dynamics shaping access to high-cost immunotherapies and biosimilars in lymphoma care across global markets
5.9. Emergence of bispecific antibodies revolutionizing treatment paradigms for relapsed non-Hodgkin lymphoma
5.10. Rising adoption of CAR T-cell therapies significantly improving outcomes in aggressive NHL subtypes
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Non-Hodgkin Lymphoma Treatment Market, by Treatment Type
8.1. Introduction
8.2. Chemotherapy
8.3. Immunotherapy
8.4. Radiation Therapy
8.5. Stem Cell Transplant
8.6. Targeted Therapy
9. Non-Hodgkin Lymphoma Treatment Market, by Cell Type
9.1. Introduction
9.2. B-cell Lymphomas
9.2.1. Burkitt Lymphoma
9.2.2. Diffuse Large B-Cell Lymphoma (DLBCL)
9.2.3. Follicular Lymphoma
9.2.4. Mantle Cell Lymphoma
9.2.5. Marginal Zone Lymphoma
9.3. NK-cell Lymphomas
9.4. T-cell Lymphomas
9.4.1. Anaplastic Large Cell Lymphoma
9.4.2. Cutaneous T-Cell Lymphoma
9.4.3. Peripheral T-Cell Lymphoma
10. Non-Hodgkin Lymphoma Treatment Market, by Route of Administration
10.1. Introduction
10.2. Intravenous Infusion
10.3. Oral
10.4. Subcutaneous Injection
11. Non-Hodgkin Lymphoma Treatment Market, by Patient Age Group
11.1. Introduction
11.2. Adult
11.3. Geriatric
11.4. Pediatric
12. Non-Hodgkin Lymphoma Treatment Market, by End User
12.1. Introduction
12.2. Ambulatory Surgical Centers
12.3. Cancer Treatment Centers
12.4. Hospitals
13. Americas Non-Hodgkin Lymphoma Treatment Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Non-Hodgkin Lymphoma Treatment Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Non-Hodgkin Lymphoma Treatment Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. AstraZeneca PLC
16.3.3. Bayer AG
16.3.4. BeiGene, Ltd.
16.3.5. Bristol-Myers Squibb Company
16.3.6. Cipla Inc.
16.3.7. Dr. Reddy’s Laboratories Ltd.
16.3.8. Eli Lilly and Company
16.3.9. F. Hoffmann-La Roche Ltd
16.3.10. Gilead Sciences, Inc.
16.3.11. GlaxoSmithKline PLC
16.3.12. Hikma Pharmaceuticals PLC
16.3.13. Intas Pharmaceuticals Ltd.
16.3.14. Kyowa Kirin Co., Ltd.
16.3.15. Lupin Ltd.
16.3.16. Merck & Co., Inc.
16.3.17. Novartis AG
16.3.18. Salvavidas Pharmaceutical Pvt. Ltd.
16.3.19. Sanofi S.A.
16.3.20. Takeda Pharmaceutical Company Limited
16.3.21. Teva Pharmaceutical Industries Ltd.
16.3.22. Zydus Pharmaceuticals
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. NON-HODGKIN LYMPHOMA TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. NON-HODGKIN LYMPHOMA TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. NON-HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHAI
FIGURE 26. NON-HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHSTATISTICS
FIGURE 27. NON-HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHCONTACTS
FIGURE 28. NON-HODGKIN LYMPHOMA TREATMENT MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. NON-HODGKIN LYMPHOMA TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY IMMUNOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY RADIATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STEM CELL TRANSPLANT, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TARGETED THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY BURKITT LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY FOLLICULAR LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MANTLE CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY MARGINAL ZONE LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY NK-CELL LYMPHOMAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ANAPLASTIC LARGE CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CUTANEOUS T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PERIPHERAL T-CELL LYMPHOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY INTRAVENOUS INFUSION, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY SUBCUTANEOUS INJECTION, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PEDIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CANCER TREATMENT CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 74. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 75. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 76. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 77. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 78. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 89. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 90. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 91. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 92. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 105. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 106. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 107. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 110. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 111. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 112. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 113. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 114. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 115. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 116. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 117. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 118. CANADA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 119. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 122. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 123. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 124. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 125. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 126. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 127. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 128. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 129. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 130. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 131. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 132. MEXICO NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 143. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 144. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 145. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 146. BRAZIL NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 155. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 156. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 157. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 158. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 159. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 160. ARGENTINA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 169. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 170. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 171. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 172. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 173. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 174. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 175. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 176. EUROPE, MIDDLE EAST & AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 181. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 182. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 183. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 184. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 185. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 186. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 188. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. UNITED KINGDOM NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 192. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 193. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 194. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 195. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 196. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 197. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 198. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 199. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 200. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 201. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 202. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 203. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 204. GERMANY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 205. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 206. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 207. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 208. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 209. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 210. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 211. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 212. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 213. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 214. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 215. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 216. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 217. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. FRANCE NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 220. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 221. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 222. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 223. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 224. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 225. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 226. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 227. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 228. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 229. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 232. RUSSIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 233. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 234. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 235. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 236. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 237. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 238. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 239. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 240. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 241. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 242. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 243. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 244. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 245. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 246. ITALY NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 247. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 248. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 249. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 250. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 251. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 252. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 253. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 254. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 255. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 256. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 257. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 258. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 259. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 260. SPAIN NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 261. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 262. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 263. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 264. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 265. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 266. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 267. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 268. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 269. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 270. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 271. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 272. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 273. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. UNITED ARAB EMIRATES NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 276. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 277. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 278. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 279. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 280. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 281. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 282. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 283. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
TABLE 284. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2030 (USD MILLION)
TABLE 285. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 286. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 287. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. SAUDI ARABIA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
TABLE 290. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2025-2030 (USD MILLION)
TABLE 291. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
TABLE 292. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY CELL TYPE, 2025-2030 (USD MILLION)
TABLE 293. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 294. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY B-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 295. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2018-2024 (USD MILLION)
TABLE 296. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY T-CELL LYMPHOMAS, 2025-2030 (USD MILLION)
TABLE 297. SOUTH AFRICA NON-HODGKIN LYMPHOMA TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MI

Samples

Loading
LOADING...

Companies Mentioned

  • AbbVie Inc.
  • AstraZeneca PLC
  • Bayer AG
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy’s Laboratories Ltd.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Hikma Pharmaceuticals PLC
  • Intas Pharmaceuticals Ltd.
  • Kyowa Kirin Co., Ltd.
  • Lupin Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Salvavidas Pharmaceutical Pvt. Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Pharmaceuticals

Table Information

Report AttributeDetails
No. of Pages191
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.26 Billion
Forecasted Market Value ( USD ) by 2030 $ 15.66 Billion
Compound Annual Growth Rate8.7%
Regions CoveredGlobal
No. of Companies Mentioned22

Related Topics

Related Reports

Non Hodgkin Lymphoma (NHL) Market Report 2025 - Product Image

Non Hodgkin Lymphoma (NHL) Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Non-Hodgkin Lymphoma Therapeutics - Global Strategic Business Report - Product Image

Non-Hodgkin Lymphoma Therapeutics - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025 - Product Image

CAR T-Cell Therapy For Non-Hodgkin's Lymphoma- - Pipeline Insight, 2025

  • Clinical Trials
  • 40 Pages
  • Global
From
CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035 - Product Image

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market - A Global and Regional Analysis: Focus on Indication, Therapy, and Region - Analysis and Forecast, 2025-2035

  • Report
  • Global
From
Lymphoma Treatment Market Size, Share & Trends Analysis Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), Region, and Segment Forecasts, 2025-2030 - Product Image

Lymphoma Treatment Market Size, Share & Trends Analysis Report by Type (Hodgkin Lymphoma, Non-Hodgkin Lymphoma), Drugs (Adcetris, Opdivo, Rituxan, Imbruvica, Keytruda), Region, and Segment Forecasts, 2025-2030

  • Report
  • 100 Pages
  • Global
From

About the Non Hodgkin Lymphoma Drug Market

The Non Hodgkin Lymphoma Drug market is a subset of the larger Lymphoma Drugs market. Non Hodgkin Lymphoma (NHL) is a type of cancer that affects the lymphatic system, and is the seventh most common cancer in the United States. Treatment for NHL typically involves chemotherapy, radiation, and targeted therapies. The Non Hodgkin Lymphoma Drug market is composed of a variety of drugs used to treat NHL, including monoclonal antibodies, small molecule drugs, and immunomodulators. These drugs are used to target specific proteins and pathways involved in the development and progression of NHL. Some of the major companies in the Non Hodgkin Lymphoma Drug market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Celgene, Eli Lilly, Genentech, Merck, Novartis, Pfizer, and Roche. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.